GlobeNewswire by notified

CoinShares and FTX Announce Partnership with the launch of CoinShares FTX Physical Staked Solana ETP

Share

Solana ETP is the first initiative between FTX and CoinShares and launches with 1M SOL in seed capital, Staking Rewards of 3.0% p.a. and a reduced management fee of 0.0% p.a.

March 23, 2022 | SAINT HELIER, Jersey - CoinShares (“the Company”) (Nasdaq First North Growth Market: CS; US OTCQX: CNSRF), Europe's largest digital asset investment firm with US$3.8bn in AUM, and FTX, a leading regulated cryptocurrency exchange, today announced a partnership between the two organizations. The first initiative in the partnership is the launch of the world’s first physically-backed Solana exchange traded product (ETP) designed to share the rewards of staking with investors in a transparent way. The ETP will launch with 1M SOL in seed capital.

The partnership with CoinShares is the latest move into the institutional landscape for FTX, following the launch of FTX Access, which offers advisory services, index products, trade execution, analytical tools and capital introductions for institutional investors interested in gaining exposure to digital assets. For CoinShares, this collaboration with FTX and FTX Access continues the Company's mission of bridging the gap between traditional finance and digital assets in a secured, transparent and familiar manner. Both organizations are at the forefront of innovation for the financial ecosystem and this partnership will continue to bridge the gap between traditional finance and digital assets.

Sam Bankman-Fried, FTX CEO, commented on the news, “The goal of FTX Access is to bring institutional-grade services and products to market in a cost-effective manner. We only want to launch products that are genuinely innovative and add value to our clients. CoinShares has a proven track record of providing European investors with innovative and regulated crypto-asset investment vehicles for close to a decade, making them the obvious choice to collaborate with for institutional offerings. We’re excited to work alongside CoinShares to give investors access to the Solana ecosystem and we look forward to collaborating further on additional offerings.”

CoinShares FTX Physical Staked Solana leverages the Company’s technology platform, Galata, that acts as a bridge between the digital asset ecosystem, connecting CeFi platforms to digital asset protocols and markets, in combination with FTX’s industry-leading institutional offerings to provide investors with exposure to Solana and the rewards for participating in the blockchain’s security. CoinShares FTX Physical Staked Solana will be listed on Germany's main market Xetra and is the fourth ETP launched by CoinShares this year.

CoinShares FTX Physical Staked Solana

Management Fee: Reduced to 0.0% p.a.

Staking Reward: 3.0% p.a.

ISIN: GB00BNRRFY34

Ticker: SLNC

WKN: A3GXNS

The Issuer formally announced by RNS on March 23, 2022, a reduction in the management fee to 0.0% p.a. and additional staking rewards of 3.0% p.a.

“At CoinShares, we have an aggressive strategy in place to drive the overall growth of the company as well as the digital asset ecosystem as a whole,” said CoinShares CEO, Jean-Marie Mognetti. “An integral piece of our growth process is establishing strategic partnerships with top-tier firms that allow us to provide our investors with additional value and increase our institutional offering, giving our clients additional market penetration. A shared goal of  FTX and CoinShares is to offer institutions means of access to cryptocurrency markets and through this partnership, both companies will be able to leverage their industry-leading technology to bring innovative products to the market.”

The unique staking mechanism allows the Issuer to share staking rewards with investors by reducing the management fee and increasing the Coin Entitlement of the ETP each day, as staking rewards accrue. Staked coins do not move from the secure custodian where they are stored, and the ETPs remain 100% physically-backed at all times.

Frank Spiteri, CoinShares Chief Revenue Officer concluded, “The feedback on our growing suite of innovative staked ETPs has been overwhelmingly positive, and collaborating with FTX to create the first Solana ETP with transparent staking rewards for investors allows us to double down on our commitment to providing investors with best-in-class regulated crypto products. Solana is one of the most requested exposures amongst our clients and SLNC is launching with 1M SOL in AUM; a level that meets institutions’ and corporates’ baseline for investment consideration.”

About the CoinShares Group

CoinShares is Europe’s largest digital asset investment firm, managing billions of assets on behalf of a global client base. Our mission is to expand access to the digital asset ecosystem by pioneering new financial products and services that provide investors with trust and transparency when accessing this new asset class. CoinShares is publicly listed on the Nasdaq First North Growth Market under ticker CS and the OTCQX under the ticker CNSRF.

CoinShares Media Contact
Jay Morakis
+1 646 859 5951
press@coinshares.com

Certified Advisor
Mangold Fondkommission AB
+46 (0)8 503 015 50
ca@mangold.se

About FTX.COM

FTX.COM is a cryptocurrency exchange built by traders, for traders. It offers innovative products, including industry-leading derivatives, options and volatility products, tokenized stocks, prediction markets, leveraged tokens and an OTC desk. FTX.COM strives to be an intuitive yet powerful platform for all kinds of users, and to be the most innovative exchange in the industry. FTX.COM has grown quickly since its founding, becoming one of the most respected cryptocurrency exchanges in the world in 2 years.

To learn more about FTX.COM, please visit: https://ftx.com

FTX.COM is not available to U.S. residents or residents of other prohibited jurisdictions, as set out in its Terms of Service.

About FTX Access

FTX Access combines the expertise behind FTX.COM and FTX US to provide institutional clients with frictionless access to digital asset products and markets globally.

To learn more about and register your interest in FTX Access, please visit: www.ftxaccess.com


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding

Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis18.5.2022 15:00:00 CEST | Press release

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of tasquinimod in this patient population.” The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives. In February 2022, Active Biotech entered into an exclusive lice

Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 202218.5.2022 14:00:00 CEST | Pressemelding

2022-05-18 PRESSRELEASE Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 2022 Idag, den 18 maj 2022, hölls årsstämma i Arcoma Aktiebolag. Årsstämman genomfördes enbart genom förhandsröstning (poströstning) med stöd av tillfälliga lagregler. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat i enlighet med styrelsens förslag i årsredovisningens förvaltningsberättelse, innebärande att ingen vinstutdelning lämnas för 2021 samt att disponibla medel balanseras i ny räkning. Ansvarsfrihet åt styrelseledamöterna och verkställande direktören Årsstämman beslutade att bevilja styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2021. Val och arvodering av styrelse och

Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM18.5.2022 13:11:14 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 May 2022 Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM Björn Wahlroos, Chair of Sampo plc’s Board of Directors, has announced today that he will not be available for re-election to the Board of Directors at the Annual General Meeting to be held in spring 2023. Sampo’s Nomination and Remuneration Committee will communicate on succession in due course. SAMPO PLC For further information, please contact: Sami Taipalus Head of Investor Relations tel. +358 10 516 0030 Distribution: Nasdaq Helsinki London Stock Exchange The principal media Financial Supervisory Authority www.sampo.com

Decisions of Sampo plc’s Annual General Meeting18.5.2022 13:05:00 CEST | Press release

SAMPO PLC DECISIONS OF GENERAL MEETING 18 May 2022 at 2:05 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 18 May 2022, decided to distribute a dividend of EUR 4.10 per share for 2021. The record date for dividend payment is 20 May 2022 and the dividend will be paid on 31 May 2022. The Annual General Meeting adopted the financial accounts for 2021 and discharged the Board of Directors and the CEO from liability for the financial year. The Annual General Meeting increased the number of the members of the Board of Directors to nine members. Christian Clausen, Fiona Clutterbuck, Georg Ehrnrooth, Jannica Fagerholm, Johanna Lamminen, Risto Murto, Markus Rauramo and Björn Wahlroos were re-elected to the Board. Steve Langan was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting. At its organisational meeting, the Board elected Björn Wahlro